Diabetic Cardiomyopathy: Molecular Pathogenesis, Metabolic Remodeling, and Emerging Pharmacological Targets

Authors

  • Amira Sobhy Mahmoud , Heba Sabry Ahmed, Nevertyty Mohamed Mahmoud, Dalia M. Abd El Motteleb

Keywords:

Diabetic cardiomyopathy, Mitochondrial dysfunction, AMPK, Cardioprotection

Abstract

Background: Diabetic cardiomyopathy (DCM) describes myocardial structural and functional abnormalities associatedwith diabetes that cannot be explained solely by coronary artery disease, hypertension, or valvular disease. Its biology is complex and includes altered insulin signaling, substrate inflexibility, mitochondrial dysfunction, oxidative stress,inflammation, endoplasmic reticulum stress, impaired calcium handling

Downloads

Download data is not yet available.

References

Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595-602.

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624-638

Downloads

Published

2024-03-20

How to Cite

Amira Sobhy Mahmoud , Heba Sabry Ahmed, Nevertyty Mohamed Mahmoud, Dalia M. Abd El Motteleb. (2024). Diabetic Cardiomyopathy: Molecular Pathogenesis, Metabolic Remodeling, and Emerging Pharmacological Targets. Pegem Journal of Education and Instruction, 14(3), 1310–1316. Retrieved from https://www.pegegog.net/index.php/pegegog/article/view/5339

Issue

Section

Article